Global Antibacterial Drugs Market 2015-2019

Global Antibacterial Drugs Market 2015-2019

Category : Pharmaceuticals
Published On : November  2015
Pages : 116



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About antibacterial drugs
Antibacterial drugs are chemical compounds used to treat infections caused by bacteria either by killing or inhibiting the growth of bacteria. The term antibiotic is often used synonymously with an antibacterial. However, antibiotics are agents that work against microorganisms such as bacteria, fungi, and parasites but are not effective against viruses. The term antibiotic was originally coined to refer to any compound of microbial origin, which is antagonistic to the growth of the microbe. Antibacterial acts via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis. They can be bacteriostatic or bactericidal in nature, i.e., they either block vital processes in bacteria, kill the bacteria, or halt them from growing. Antibiotics that affect a wide range of bacteria are called broad-spectrum antibiotics (e.g., amoxicillin and gentamicin). Antibiotics that affect only a few types of bacteria are called narrow spectrum antibiotics (e.g., penicillin).

Technavio's analysts forecast the global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019.

Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The various classes of antibacterial drug included in this report are beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, folate antagonists, tetracyclines, and other miscellaneous agents, which include glycopeptides, nitroimidazoles, lincosamides, lipopeptides, nicotinic acid derivatives, and polypeptide antibiotics.

Technavio's report, Global Antibacterial Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
• Americas
• APAC
• EMEA 

Key vendors
• Allergan
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
• Teva Pharmaceuticals

Other prominent vendors
• Abbott
• Achaogen
• Actelion
• AmpliPhi Biosciences
• Aspen Pharmacare
• Astellas
• AstraZeneca
• Aurobindo Pharma
• Baxter
• Basilea Pharmaceuticals
• Bayer
• Biocon
• Bristol-Myers Squibb
• Cempra
• Cipher Pharmaceuticals
• Corden Pharma
• Cornerstone Therapeutics
• Eli Lilly
• Exoxemis
• F. Hoffmann-La Roche 
• Flynn Pharma
• Hospira
• Incepta Pharmaceuticals
• InSite Vision
• Insmed Incorporated
• Johnson & Johnson
• KaloBios Pharmaceuticals
• Kyorin Pharmaceutical
• Lupin Pharmaceuticals
• Lytix Biopharma
• Melinta Therapeutics
• Mylan
• Nektar
• Orchid Pharma
• Par Pharmaceutical
• Paratek Pharmaceuticals 
• Pernix Therapeutics
• PTC Therapeutics
• RedHill Biopharma
• Sagent Pharmaceuticals
• Sanofi 
• Shionogi
• Starpharma
• Sun Pharmaceutical
• Symbiomix 
• Takeda Pharma
• Tetraphase Pharmaceuticals
• Theravance Biopharma
• The Medicines Company
• Valneva 
• Wockhardt Global Solutions
 
Key market driver
• Special regulatory designations
• For a full, detailed list, view our report

Key market challenge
• Development of drug-resistant strains
• For a full, detailed list, view our report

Key market trend
• Strategic alliances and M&A
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Antibacterial: overview
Introduction
Mechanism of action
General principles for the use of antibiotics
Clinical uses
Epidemiology

PART 06: Pipeline analysis
Zerbaxa
Surotomycin
MK-3415A
Amikacin Inhale
CARBAVANCE
Eravacycline
Plazomicin
Delafloxacin
Solithromycin
VivaGel
Arikayce
Cadazolid
Ozenoxacin

PART 07: Antimicrobial resistance
Sources of spread of resistant organisms
Initiatives to improve antibiotic innovation

PART 08: Legislation relating to antibiotic use in the US

PART 09: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 10: Market segmentation by chemical class
Beta-lactam
Macrolides
Aminoglycosides
Phenicols
Quinolones
Folate antagonists
Tetracyclines
Others

PART 11: Market segmentation by drug origin
Natural
Semisynthetic
Synthetic

PART 12: Market segmentation by mechanism of action
Bacteriostatic
Bactericidal

PART 13: Market segmentation by spectrum of activity
Broad spectrum antibiotics
Narrow spectrum antibiotics

PART 14: Geographical segmentation
Global antibacterial drugs market by geographical segmentation 2014-2019
Antibacterial drugs market in APAC
Antibacterial drugs market in EMEA
Antibacterial drugs market in Americas

PART 15: Market drivers
Special regulatory designations
Increase in prevalence of infections
Increase in awareness
Increase in aging population

PART 16: Impact of drivers

PART 17: Market challenges
Development of drug resistant strains
Patent expiries and generic penetration
Decreased investments in research activities

PART 18: Impact of drivers and challenges

PART 19: Market trends
Strategic alliances and M&A
Patient assistance programs
Increased funding on antibiotic research

PART 20: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 21: Key vendor analysis
Allergan
GSK
Merck
Pfizer
Sandoz
Teva Pharmaceuticals

PART 22: Appendix
List of abbreviation

PART 23: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Mechanism of action of antibacterial drugs
Exhibit 03: General principles involved in the use of antibiotics
Exhibit 04: Estimated number of cases for nosocomial infections in US, 2011
Exhibit 05: Number of cases for Escherichia coli bacteremia in UK, 2012-2014
Exhibit 06: Global antibacterial drugs market: Pipeline portfolio
Exhibit 07: Causes of antimicrobial resistance
Exhibit 08: Sources of spread of resistant organisms
Exhibit 09: Estimated deaths per year caused by AMR in 2050
Exhibit 10: Initiatives improving antibiotic innovation
Exhibit 11: Legislation relating to antibiotic use in US
Exhibit 12: Global antibacterial drugs market 2014-2019 ($ billions)
Exhibit 13: Five forces analysis
Exhibit 14: Global antibacterial drugs market segmentation by chemical class
Exhibit 15: Cephalosporin segmentation by generation of drugs
Exhibit 16: Global antibacterial drugs market revenue segmentation by chemical class
Exhibit 17: Global antibacterial drugs market segmentation by drug origin
Exhibit 18: Global antibacterial drugs market segment by geography 2014
Exhibit 19: Antibacterial drugs market revenue by geography 2014-2019 ($ billions)
Exhibit 20: Antibacterial drugs market in APAC 2014-2019 ($ billions)
Exhibit 21: Antibacterial drugs market in EMEA 2014-2019 ($ billions)
Exhibit 22: Antibacterial drugs market in Americas 2014-2019 ($ billions)
Exhibit 23: Percentage share of antibacterial drugs market in Americas
Exhibit 24: Impact of drivers
Exhibit 25: Antibiotic-resistant strains according to the period of development of resistance
Exhibit 26: Antibacterial drug approvals by FDA and EMA
Exhibit 27: Impact of drivers and challenges
Exhibit 28: Allergan: YoY growth and revenue generated from net product sales of anti-infective 2011-2013 ($ millions)
Exhibit 29: Allergan: Key takeaways
Exhibit 30: GlaxoSmithKline: YoY growth and revenue generated from sales of Augmentin 2011-2014 ($ millions)
Exhibit 31: GlaxoSmithKline: Revenue generated from sales of Augmentin by region 2011-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: YoY growth and revenue generated from sales of other antibacterials 2011-2013 ($ millions)
Exhibit 33: GlaxoSmithKline: Key takeaways
Exhibit 34: Merck: YoY growth and revenue generated from sales of Primaxin 2012-2014 ($ millions)
Exhibit 35: Merck: YoY growth and revenue generated from sales of Invanz 2012-2014 ($ millions)
Exhibit 36: Merck: Key takeaways
Exhibit 37: Pfizer: YoY growth and revenue generated from sales of Zyvox 2012-2014 ($ millions)
Exhibit 38: Pfizer: YoY growth and revenue generated from sales of Zithromax/Zmax 2012-2014 ($ millions)
Exhibit 39: Pfizer: YoY growth and revenue generated from sales of Unasyn 2012-2014 ($ millions)
Exhibit 40: Pfizer: YoY growth and revenue generated from sales of Zosyn/Tazocin 2012-2014 ($ millions)
Exhibit 41: Pfizer: YoY growth and revenue generated from sales of Sulperazon 2012-2014 ($ millions)
Exhibit 42: Pfizer: YoY growth and revenue generated from sales of Tygacil 2012-2014 ($ millions)
Exhibit 43: Pfizer: Key takeaways
Exhibit 44: Sandoz: Key takeaways
Exhibit 45: Teva Pharmaceuticals: Key takeaways
Exhibit 46: Allergan: Business segmentation by product revenue 2014
Exhibit 47: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 48: Allergan: Geographical segmentation by revenue 2014
Exhibit 49: GSK: Business segmentation by revenue 2014
Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 51: GSK: Geographical segmentation by revenue 2014
Exhibit 52: Merck: Business segmentation by revenue 2014
Exhibit 53: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 54: Merck: Geographical segmentation by revenue 2014
Exhibit 55: Pfizer: Business segmentation by revenue 2014
Exhibit 56: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 57: Pfizer: Geographical segmentation by revenue 2014
Exhibit 58: Sandoz: Business segmentation by revenue 2014
Exhibit 59: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 60: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
Exhibit 61: Teva Pharmaceuticals: Geographical segmentation by revenue 2014

Enquiry Before Buy
image
Can´t read the image ? refresh here.